KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) Income from Non-Controlling Interests (2019 - 2020)

Inovio Pharmaceuticals (INO) has disclosed Income from Non-Controlling Interests for 8 consecutive years, with -$469407.0 as the latest value for Q2 2020.

  • Quarterly Income from Non-Controlling Interests fell 144.67% to -$469407.0 in Q2 2020 from the year-ago period, while the trailing twelve-month figure was -$469407.0 through Mar 2021, up 72.67% year-over-year, with the annual reading at -$1.1 million for FY2020, 10.8% up from the prior year.
  • Income from Non-Controlling Interests hit -$469407.0 in Q2 2020 for Inovio Pharmaceuticals, up from -$594350.0 in the prior quarter.
  • In the past five years, Income from Non-Controlling Interests ranged from a high of -$69605.0 in Q1 2019 to a low of -$594350.0 in Q1 2020.